Daewoong Pioneers First-Ever NK Cell Technology Transfer to Indonesia, Advancing Anti-Cancer Treatment

Manager
2025-01-15


Daewoong Pioneers First-Ever NK Cell Technology Transfer to Indonesia, Advancing Anti-Cancer Treatment

 

  • Opening a New Era of NK Cell Therapy in Indonesia: From No Options to Advanced Solutions
  • Daewoong’s differentiated Technology enables high-quality NK cell production
  • Hope for Cancer Patients: Indonesia Gains Access to Innovative Cancer Treatments with Daewoong's NK Cell Therapy

 

(Jakarta, 15 January 2025) Daewoong transfers advanced NK cell technology to Indonesia, marking a milestone in anti-cancer treatment in Indonesia.

 

Daewoong has announced the successful transfer of cutting-edge natural killer (NK) cell technology to Indonesia, installing the country's first-ever GMP-grade NK cell technology at Daewoong Biologics Indonesia, a Daewoong affiliate.

 

This groundbreaking initiative includes the transfer of GMP-grade NK cell manufacturing and analysis techniques and method validation, storage and transportation methods, and commercialization strategies, solidifying the foundation for advanced regenerative medicine in Indonesia.

 

Prior to this transfer, Indonesia had no local production of GMP-approved NK cell therapies, severely restricting access to innovative cancer treatments. This transfer introduces, for the first time, the production and supply of high-quality NK cell therapies, catalyzing Indonesia's oncology market and offering cutting-edge treatment options to cancer patients in need.

 

Daewoong's proprietary NK cell manufacturing technology, implemented at Daewoong Biologics Indonesia's facility, exhibits unique strengths in mass production while prioritizing cell activity and safety. Unlike conventional methods that rely on feeder cells, which pose potential safety concerns, Daewoong's innovative approach offers a significant technological advantage, enhancing quality.

 

Specifically, in terms of quality, Daewoong's NK cells demonstrate an average cell viability of 95%, underpinned by high expression of surface markers and genes associated with anti-cancer activity. In terms of productivity, this is facilitated by a unique stimulator. This eliminates the need for feeder cells while achieving production levels comparable to, and even exceeding, those obtained using feeder cells.

 

This initiative underscores Daewoong's commitment to expanding the reach of advanced regenerative medical technology globally, as part of its vision to provide innovative NK cell therapies. Leveraging its advanced manufacturing skills and production know-how, Daewoong Pharmaceutical is set to create sustainable environments for producing high-quality cell therapies in regions facing shortages.

 

Baik In Hyun, Head of Daewoong Biologics Indonesia’s business unit stated that "As highlighted in a recent OECD report, cancer remains the third leading cause of mortality in Indonesia. The integration of advanced NK cell therapies represents a significant step toward improving patient outcomes and reducing cancer-related mortality" and "We are committed to leveraging this innovative technology to not only enhance the quality of cancer care in Indonesia but also set a new benchmark for personalized treatments in the region.”

 

Daewoong Biologics Indonesia plans to solidify its leadership in the cutting-edge cell therapy market by establishing stable production and supply systems. This transfer is not just about importing technology but also about sparking growth in Indonesia's biopharmaceutical industry and enhancing local cancer treatment standards. Moreover, there is an ambition to enter global markets, using innovative cell therapies to improve the quality of life for cancer patients worldwide. Driven by ongoing research and development, Daewoong Biologics Indonesia is poised to lead the regenerative medicine sector while advancing its vision to become a global healthcare frontrunner.

 

For over two decades, Daewoong has been deeply committed to fostering shared growth with Indonesia since the opening of its Jakarta branch in 2005. In 2012, Daewoong further solidified its dedication by establishing Daewoong Infion, Indonesia’s first biopharmaceutical production facility, facilitating technology transfer for biopharmaceutical manufacturing and offering Halal-certified EPO and EGF medicines. Daewoong’s EPO API quickly secured a dominant market share within six months of its Indonesian launch and is now exported to South Korea. To fortify local production capabilities, Daewoong completed the construction of a state-of-the-art stem cell therapy facility in Indonesia in 2024. This 20-year journey exemplifies Daewoong’s unwavering commitment to mutual growth and innovation in partnership with Indonesia.

 

- # # # -